Smith & Nephew’s Neutral Rating Reaffirmed at JPMorgan Chase & Co. (SN)
Smith & Nephew (LON:SN)‘s stock had its “neutral” rating reiterated by equities research analysts at JPMorgan Chase & Co. in a research note issued to investors on Thursday, American Banking News.com reports. They currently have a GBX 791 ($12.97) target price on the stock. JPMorgan Chase & Co.’s price target suggests a potential downside of 9.13% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Deutsche Bank reiterated a “hold” rating on shares of Smith & Nephew in a research note to investors on Thursday. They now have a GBX 650 ($10.66) price target on the stock. Separately, analysts at Galvan Research reiterated a “buy” rating on shares of Smith & Nephew in a research note to investors on Thursday, January 2nd. They now have a GBX 920 ($15.09) price target on the stock. Finally, analysts at Galvan Research reiterated a “buy” rating on shares of Smith & Nephew in a research note to investors on Monday, December 16th. They now have a GBX 890 ($14.60) price target on the stock. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have issued a buy rating to the stock. Smith & Nephew presently has a consensus rating of “Hold” and an average target price of GBX 803.06 ($13.17).
Smith & Nephew (LON:SN) traded up 0.23% during mid-day trading on Thursday, hitting GBX 870.50. 1,856,669 shares of the company’s stock traded hands. Smith & Nephew has a 1-year low of GBX 683.00 and a 1-year high of GBX 878.00. The stock’s 50-day moving average is GBX 835.8 and its 200-day moving average is GBX 792.9. The company’s market cap is £7.826 billion.
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.